Cannabis and Healthy Ageing: Anti-Aging Effects of Cannabis in Animal and Human Studies

Cannabis, the Endocannabinoid System, and Ageing

Over recent decades, scientists have become increasingly interested in the endocannabinoid system (ECS)—the brain's internal signalling network that runs off cannabinoids. Instead of phytocannabinoids (from plants), these are endocannabinoids, produced naturally by our bodies. Researchers theorise that the ECS is a key process in keeping neural circuits resilient and functional as we age.

In older brains, ECS activity tends to run low, which is partially why memory and learning decline over time. Recent animal studies on cannabis and ageing have leaned into this idea, and so far, the results have been striking: in several controlled experiments, cannabinoid dosages appeared to restore youthful brain function.

Human studies are more mixed and need stronger design and controls, but there is growing evidence cannabis may correlate with less cognitive decline across certain groups.

The Classic “Youthening” Mouse Study (and Why It Mattered)

The watershed moment came in 2017, when a landmark paper published in Nature Medicine showed that older mice given chronic, ultra-low doses of THC regained lost memory skills and learning abilities to levels seen in young mice.

Mechanistically, the THC treatment:

• Boosted synaptic marker proteins

• Increased hippocampal spine density

• Shifted gene-expression profiles towards a more youthful state

Interestingly, the same THC regimen impaired cognition in young mice, strengthening the argument that cannabis is best used when the brain is fully developed. Even more, while THC alone provided the benefits, adding CBD in a 1:1 ratio blunted the effect—highlighting how cannabinoid ratios make a difference.

What’s New in 2024–2025: More Animal Data, More Nuance

CBN (Cannabinol) and Mitochondrial/Synaptic Health

A 2025 open-access study in the SAMP8 accelerated-ageing mouse model found that CBN improved spatial learning and memory, especially in females. The cannabinoid also up-regulated mitochondrial biogenesis markers (TFAM, TOM20) and synaptic proteins (PSD-95). Translation: better energy handling and synaptic strength tracked with improved cognition.

CBD and Longevity Pathways

Several preclinical studies show CBD may extend lifespan and healthspan in C. elegans (nematodes). This effect is tied to autophagy (the body’s “cell clean-up” process) via the sir-2.1/SIRT1 pathway, which is well known in ageing biology.

• A 2022 study found CBD-induced autophagic flux improved neuronal health, and the lifespan extension was dependent on autophagy genes.

• While worms are not humans, these pathways are conserved across species, making them promising markers for future ageing research.

Mechanistic Through-Line

Across animal models, cannabinoids in older organisms consistently show:

• Reinforced synaptic structure (spine density and stability)

• Restoration of “youthful” gene-expression programs in the hippocampus

• Improved mitochondrial function and energy biogenesis

• Activation of autophagy pathways

Together, these findings suggest that the endocannabinoid system may be a pro-homeostatic target for healthy ageing, though over-generalising rodent/worm data to humans remains risky.

Human Studies: Where Cannabis and Cognitive Ageing Intersect

This is where the picture gets more complex—but also more exciting.

Longitudinal Cohort (Denmark)

In a 44-year follow-up study of 5,162 men, those with a history of cannabis use showed slightly less cognitive decline than non-users (about 1.3 IQ points less decline after adjustment). While modest, this suggests cannabis use did not accelerate age-related decline and may have a mild protective correlation.

U.S. Population Snapshot (BRFSS, 2021)

A 2024 analysis of U.S. adults aged 45+ reported lower odds of subjective cognitive decline among recreational cannabis users compared to non-users. Though cross-sectional (and unable to prove causation), this finding suggests cannabis use may not always be detrimental for mid- to late-life brain health.

Systematic Reviews of Older Adults

• A 2019 review concluded that we lack robust, controlled trials on cannabis and cognition in older adults.

• A 2020 review highlighted the scarcity of data in healthy ageing cohorts.

Alzheimer’s and Related Disorders

Clinical trials with dronabinol and nabilone in Alzheimer’s patients show:

• Reduced agitation

• Improved behavioural symptoms

• Acceptable tolerability

These outcomes are critical for quality of life, but the studies were not designed to measure cognitive improvements directly.

A Necessary Caution

Large-scale neuroimaging in younger adults shows heavy cannabis use is linked to:

• Reduced working-memory-related brain activity

• Short-term impairments in attention and executive function

These effects tend to resolve with abstinence, but they highlight that dose, age of first use, and recency of use matter significantly.

Why Age, Dose, and Molecule Matter in Cannabis and Ageing

• Age: Low-dose THC helps old mice but harms young mice, likely due to different ECS tone and plasticity needs.

• Dose: Most beneficial rodent effects appear at ultra-low doses over weeks—not at intoxicating levels.

• Chemotype:

  • THC drives synaptic and epigenetic rejuvenation in older brains.

  • CBD supports autophagy and cellular maintenance in ageing models.

  • CBN boosts mitochondrial and synaptic health, with some sex-specific effects.

This means future clinical trials in humans will need to carefully stratify by age, dose, and cannabinoid profile.

Practical Takeaways (Not Medical Advice)

• Cannabis is not yet a proven anti-ageing therapy in humans. Current strongest evidence relates to symptom relief (e.g., agitation in dementia) rather than cognitive decline prevention.

• Risks remain: higher THC, polypharmacy, cardiovascular issues, fall risk, and intoxication all matter.

• What’s next? Trials of low-dose THC, CBD, and CBN in older adults, with rigorous cognitive endpoints and biomarkers like synaptic proteins and autophagy markers.

In One Paragraph: Where the Science Stands

In animals—especially older mice—carefully dosed cannabinoids can reverse age-related cognitive deficits and restore youthful brain features. Low-dose THC is the most replicated example, while CBN and CBD show promise for mitochondrial and longevity pathways. In humans, evidence is still preliminary but not negative: a 44-year Danish study linked cannabis use with slightly less decline, and a U.S. analysis found lower odds of subjective cognitive decline among users. Still, acute intoxication and heavy use—especially in young adults—impair cognition. The consensus: the ECS is a credible anti-ageing target, but age, dose, and cannabinoid type will determine outcomes.